无论是tasocitinib还是Incyte的药物，INCB 028050，都是目标直指激酶，通过一种叫做细胞因子的免疫系统蛋白介导信号。
Both tasocitinib and Incyte's drug, INCB028050, target Janus kinases, which mediate signalling by immune-system proteins called cytokines.
肿瘤药物主要是通过抑制一种下调通路，从而简介导致细胞死亡。
Oncology drugs act primarily by inhibiting a deregulated pathway, which indirectly leads to cell death.
用两种乳腺癌细胞株模型评价纳米粒介导的细胞药物释放动力学和机理及纳米粒包囊阿霉素的治疗效果。
Kinetics and mechanism of nanoparticle-mediated cellular drug delivery and therapeutic efficacy of nanoparticle-encapsulated doxorubicin were evaluated in two model breast cancer cell lines.
应用推荐